MARKET IS OPEN
Loading latest tickers...
Market Indices
S&P 500
$7,773.95
+0.66%
NASDAQ 100
$31,076.44
+0.87%
DOW JONES
$51,268.00
+0.18%
NASDAQ Composite
$27,477.31
+1.05%
RUSSELL 2000
$2,833.80
+0.66%
CBOE VIX
$15.52
+1.37%
Sector Heatmap
Technology+0.56%
Financials+0.73%
Healthcare+0.72%
Consumer Cycl+0.35%
Consumer Staples+0.63%
Energy+0.99%
Industrials+0.09%
Materials+1.31%
Real Estate-0.34%
Utilities+0.35%
Comm Services+1.17%
LENZ — LENZ Therapeutics, Inc. Common Stock
NasdaqLENZ Therapeutics, Inc. Common Stock
$3.59
+0.01(+0.28%)
- O
- 3.60
- H
- 3.60
- L
- 3.46
- V
- 777.36K
⏱️ End-of-day dataAs of Oct 5, 2026
Chart
About LENZ
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateMar 22, 2024
Employees152
Stock ExchangeNasdaq
Ticker SymbolLENZ
Websitehttps://www.lenz-tx.com
Key Financial Statistics
| Market Cap | $112.48M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $3.46 - $49.25 |
| 52-Week Avg Volume | 990.6K |
| VWAP | $3.53 |
| Transactions | 6,017 |
| Total Recorded Bars | 1,325 days |